A new study published online by JAMA Neurology examines the long-term outcomes of patients with aggressive forms of multiple sclerosis (MS) who failed to respond to standard therapies and who ...

U.S. regulators have approved the first drug for an aggressive kind of multiple sclerosis that steadily reduces coordination and the ability to walk. The Food and Drug Administration approved Ocrevus ...